Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery

Med Sci Monit Basic Res. 2016 Mar 9:22:27-33. doi: 10.12659/MSMBR.897505.

Abstract

Background: The current study was performed to investigate the effect of adenosine monophosphate (AMP) - activated protein kinase (AMPK) activation on the extracellular matrix (ECM) remodeling of pulmonary arteries in pulmonary arterial hypertension (PAH) and to address its potential mechanisms.

Material and methods: PAH was induced by a single intraperitoneal injection of monocrotaline (MCT) into Sprague-Dawley rats. Metformin (MET) was administered to activate AMPK. Immunoblotting was used to determine the phosphorylation and expression of AMPK and expression of tissue inhibitor of metalloproteinase-1 (TIMP-1). Gelatin zymography was performed to determine the activity of matrix metalloproteinase-2 (MMP-2) and MMP-9.

Results: Activation of AMPK by MET significantly reduced the right ventricle systolic pressure and the right ventricular hypertrophy in MCT-induced rat PAH model, and partially inhibited the ECM remodeling of pulmonary arteries. These effects were coupled with the decrease of MMP-2/9 activity and TIMP-1 expression.

Conclusions: This study suggests that activation of AMPK benefits PAH by inhibiting ECM remodeling of pulmonary arteries. Enhancing AMPK activity might have potential value in clinical treatment of PAH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Disease Models, Animal
  • Enzyme Activation / drug effects
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / enzymology
  • Extracellular Matrix / pathology
  • Hypertension, Pulmonary / enzymology
  • Hypertension, Pulmonary / pathology
  • Male
  • Matrix Metalloproteinase 2 / metabolism
  • Metformin / pharmacology
  • Monocrotaline / pharmacology*
  • Pulmonary Artery / drug effects*
  • Pulmonary Artery / enzymology*
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • Vascular Remodeling / drug effects*

Substances

  • Tissue Inhibitor of Metalloproteinase-1
  • Monocrotaline
  • Metformin
  • AMP-Activated Protein Kinases
  • Matrix Metalloproteinase 2